Veradigm (NASDAQ:MDRX) Shares Up 14.1% - What's Next?

Key Points

• Veradigm Inc. shares surged 14.1% to $5.25 during trading, although this volume was significantly lower than the average, at only 1,535 shares compared to approximately 250,930.
• Wall Street analysts, including Wall Street Zen, have initiated coverage with a "hold" rating and set a consensus price target of $13.00 for the stock.
• Veradigm is a healthcare technology company offering solutions such as electronic health records and analytics, primarily servicing healthcare organizations in the U.S. and internationally.

Veradigm Inc. (NASDAQ:MDRX - Get Free Report)'s stock price shot up 14.1% during mid-day trading on Friday . The stock traded as high as $5.25 and last traded at $5.25. 1,535 shares were traded during mid-day trading, a decline of 99% from the average session volume of 250,930 shares. The stock had previously closed at $4.60.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen started coverage on Veradigm in a research note on Tuesday, May 20th. They set a "hold" rating on the stock. One analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $13.00.

Veradigm Stock Up 1.1%

The firm has a 50 day moving average price of $4.77 and a two-hundred day moving average price of $4.57.

Veradigm Company Profile

Veradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.